GlassScriptPhysician profile
Regina L Sun
NPI 1104852466
$6,915.78
in general payments reported to CMS, 2019-2025
27 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $112 · 2021: $269 · 2022: $2,481 · 2023: $1,287 · 2024: $934 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,570.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,570.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,035.46 | 2019-2025 | Clareon, Unity, Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $1,075.90 | 2022-2025 | Durysta, Lumigan, Vuity |
| Glaukos Corporation | $324.33 | 2022-2025 | Idosetr, Istent Infinite |
| Novartis Pharmaceuticals Corporation | $269.25 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $245.30 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $242.15 | 2022-2025 | Xiidra, Miebo, Vyzulta |
| Amgen INC. | $214.23 | 2024-2025 | Tepezza |
| Shire North American Group INC | $167.47 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $157.47 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $150.80 | 2022-2023 | Tepezza |
| Rxsight INC | $142.28 | 2022-2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Adjustable Lens (Rxlal) |
| Allergan, INC. | $133.53 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $108.31 | 2022-2023 | Tecnis Iol |
| Kala Pharmaceuticals, INC. | $95.76 | 2019-2021 | |
| Carl Zeiss Meditec USA, INC. | $84.97 | 2023 | Iolmaster 700 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $75.68 | 2024-2025 | Vevye |
| Oyster Point Pharma, INC. | $59.37 | 2022-2023 | Tyrvaya |
| Biotissue Holdings INC. | $56.59 | 2023-2024 | |
| Dompe US, INC. | $48.46 | 2021-2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $48.15 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $44.58 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $36.90 | 2019-2021 | |
| Medtronic, INC. | $28.98 | 2025 | Valleylab Ft10 |
| Mallinckrodt Enterprises LLC | $19.63 | 2019 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Santen INC. | $15.68 | 2023 | Verkazia |
| New World Medical,INC. | $15.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Regina Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.